Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium chlorosum (DAC N-055) is a pro-oxidative pharmaceutical preparation containing sodium chlorite (NaClO2) at concentrations typically ranging from 0.045% to 0.09%. It is enriched with oxygen, notably containing Na2Cl2O6 (formerly known as tetradecachlorooxygen or TCDO). Under acidic conditions, in the presence of specific catalysts (heme, manganese-porphyrins), or after UVA exposure, DAC N-055 releases strong microbicidal oxidants like ClO2 and singlet oxygen. It has shown anti-infective, immunomodulatory, and tissue repair-promoting effects. Historically monographed in the German Drug Codex (1989-2014), DAC N-055 has been used in clinical applications for treating cutaneous leishmaniasis and promoting wound healing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium chlorosum.